- Tablets, disintegrating, oral 0.125 mg
- Tablets, disintegrating, oral 0.25 mg
- Tablets, disintegrating, oral 0.5 mg
- Tablets, disintegrating, oral 1 mg
- Tablets, disintegrating, oral 2 mg
- Tablets, oral 0.5 mg
- Tablets, oral 1 mg
- Tablets, oral 2 mg
CO Clonazepam (Canada)
Sandoz Clonazepam (Canada)
Potentiates action of GABA, the major inhibitory neurotransmitter in the CNS.
Rapidly and completely absorbed. Approximately 90% bioavailable. T max is 1 to 4 h.
Approximately 85% protein bound.
Highly metabolized in the liver; CYP-450, including CYP3A4, may play a major role in oxidation and reduction of clonazepam.
The half-life is 30 to 40 h. Less than 2% is excreted in the urine as unchanged drug.
Special PopulationsRenal Function Impairment
Effects of renal disease on clonazepam pharmacokinetics have not been studied.Hepatic Function Impairment
Effects of liver disease on clonazepam pharmacokinetics have not been studied.Elderly
Controlled pharmacokinetic studies have not been conducted.Children
Controlled pharmacokinetic studies have not been conducted.Gender
Controlled pharmacokinetic studies have not been conducted.
Indications and Usage
For the treatment of Lennox-Gastaut syndrome, alone or as an adjunct; for the management of akinetic and myoclonic seizures and absence seizures unresponsive to succinimides; for the treatment of panic disorders with or without agoraphobia.
Treatment of restless legs syndrome; parkinsonian dysarthria; manic or mixed episodes of bipolar disorder; multifocal tic disorders or Tourette syndrome; neuralgias (deafferentation pain syndromes); adjunctive therapy for schizophrenia.
Hypersensitivity to benzodiazepines; acute narrow-angle glaucoma; significant liver disease.
Dosage and AdministrationPanic Disorder
PO Start with 0.25 mg twice daily. An increase to the target dose for most patients of 1 mg/day may be made after 3 days. Dose may be increased in increments of 0.125 to 0.25 mg twice daily every 3 days until panic disorder is controlled or adverse effects make further increases undesired (max, 4 mg/day). When discontinuation is necessary, decrease dose gradually, with a decrease of 0.125 mg twice daily every 3 days until the drug is completely withdrawn.Seizure Disorders
Adults and Children older than 10 y or more than 30 kg
PO Do not exceed 1.5 mg/day in 3 divided doses initially. Increase by 0.5 to 1 mg every 3 days until seizures are adequately controlled or adverse effects make further increases undesirable (max, 20 mg/day).Infants and Children 10 y and younger or 30 kg or less
PO 0.01 to 0.03 mg/kg/day in 2 to 3 divided doses (max, 0.05 mg/kg/day) initially. Increase by no more than 0.25 to 0.5 mg every 3 days until a maintenance dose of 0.1 to 0.2 mg/kg has been reached, unless seizures are controlled or adverse effects make further increases undesirable.
- To reduce the inconvenience of somnolence when treating patients with panic disorder, administration of 1 dose at bedtime may be desirable.
- When treating seizure disorder, dosage should be divided into 3 equal doses whenever possible. If doses are not equally divided, give the largest dose at bedtime.
- Do not open the carton containing orally disintegrating tablets until immediately before the dose is to be administered.
- The orally disintegrating tablet disintegrates rapidly in saliva and may be swallowed with or without water.
Store between 59° and 86°F.
Drug InteractionsAlcohol and CNS depressants (eg, barbiturates, opioids, tricyclic antidepressants)
May cause additive CNS depressant effects. Avoid coadministration with alcohol.Azole antifungals (eg, itraconazole, ketoconazole, voriconazole), cimetidine, disulfiram, nefazodone, oral contraceptives, protease inhibitors (eg, ritonavir, nelfinavir)
May decrease the metabolism of clonazepam, thereby increasing the pharmacologic and toxic effects. Clonazepam dosage adjustment may be needed.Clozapine
Ataxia, delirium, sedation, and sialorrhea may occur with coadministration. Severe orthostatic hypotension and respiratory depression may occur when clozapine is added to, or started with, clonazepam. Do not start agents simultaneously. The addition of clonazepam to an established clozapine regimen may carry less risk than adding clozapine to clonazepam. Careful clinical monitoring is advised, especially during the first 48 hours of coadministration.CYP-450 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort)
May reduce clonazepam serum concentrations, decreasing the clinical effect.Digoxin
May increase serum digoxin concentrations. Monitor digoxin levels and adjust digoxin dosage as needed.Methadone
Coadministration may substantially increase the risk of a potentially fatal outcome because of potentiation of respiratory depressant effects. Use with caution.Omeprazole
Serum concentrations and pharmacologic effects of clonazepam may be increased. Toxicity may occur. If an interaction is suspected, lower the dosage of clonazepam or discontinue one or both drugs.Propantheline
Coadministration of propantheline with clonazepam orally disintegrating tablets produced decreased clonazepam AUC (by 10%) and C max (by 20%).Sodium oxybate
May result in increased sleep duration and CNS depression. Coadministration is contraindicated.Theophyllines
May antagonize sedative effects.Valproic acid
Toxicity of clonazepam may be increased, while the therapeutic effects of both drugs may be reduced (increased seizure risk). Teratogenic effects of both agents during the first trimester may be enhanced.
Drowsiness, somnolence (50%); ataxia (30%); behavior problems (25%); dizziness (12%); abnormal coordination, fatigue (9%); depression (8%); memory disturbance (5%); dysarthria, nervousness, reduced intellectual ability (4%); decreased libido (3%); confusion, emotional lability (2%); aggressive behavior, agitation, amnesia, anxiety, aphonia, choreiform movements, coma, dysdiadochokinesis, excitability, hallucinations, headache, hemiparesis, hostility, hypotonia, hysteria, increased libido, insomnia, irritability, nervousness, nightmares, psychosis, sleep disturbances, slurred speech, tremor, vertigo, vivid dreams.
Hair loss, hirsutism, skin rash.
Rhinitis (4%); blurred vision, pharyngitis (3%); abnormal eye movements, diplopia, glassy-eyed appearance, nystagmus, rhinorrhea.
Constipation (5%); decreased appetite (3%); abdominal pain (2%); anorexia, coated tongue, diarrhea, dry mouth, encopresis, gastritis, increased appetite, nausea, sore gums.
Dysmenorrhea (6%); colpitis (4%); impotence (3%); delayed ejaculation, micturition frequency, UTI (2%); dysuria, enuresis, nocturia, urinary retention.
Anemia, eosinophilia, leukopenia, thrombocytopenia.
Hepatomegaly, transient elevations of serum transaminases and alkaline phosphatase.
Myalgia (4%); muscle weakness, pains.
Upper respiratory tract infection (10%); sinusitis (8%); coughing (4%); bronchitis (2%); chest congestion, hypersecretion in upper respiratory tract passages, respiratory depression, shortness of breath.
Influenza (5%); allergic reaction (4%); ankle and facial edema, dehydration, fever, general deterioration, lymphadenopathy, weight loss or gain.
Ensure that CBC with differential and liver enzymes are evaluated periodically in patients on prolonged therapy. Ensure that therapy is periodically reviewed to determine if it needs to be continued without change or if a dose change (eg, increase, decrease, discontinuation) is indicated. Monitor patients for emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Category D . Clonazepam is assumed to be capable of causing an increased risk of congenital abnormalities.
Excreted in breast milk. Breast-feeding is not recommended.
Safety and efficacy not established.Seizure disorders
Long-term use may cause adverse effects, such as delayed mental or physical development.
Initiate with low doses and observe closely; confusion and oversedation may occur.
Use drug with caution to avoid accumulation.
Use drug with caution to avoid accumulation; contraindicated in patients with significant liver disease.
Causes CNS depression; caution patients against engaging in hazardous occupations requiring mental alertness.
Withdrawal symptoms of the barbiturate type may occur.
Because an increase in salivation may occur, use with caution in patients who have difficulty handling secretions or those with chronic respiratory disease.
In patients with multiple seizure types, clonazepam may increase incidence or precipitate onset of tonic-clonic seizures.
Suicidal behavior and ideation
Antiepileptic drugs increase the risk of suicidal thinking and behavior in patients taking these drugs for any indication.
Abrupt discontinuation, particularly in patients on long-term, high-dose therapy, may precipitate status epilepticus. If treatment is to be discontinued or the dose reduced, gradually taper the dose and monitor patient for withdrawal symptoms.
Coma, confusion, diminished reflexes, somnolence.
- Advise patients or caregivers to read the Medication Guide before starting therapy and with each refill.
- Inform patients that, because benzodiazepines may produce psychological and physical dependence, it is advisable that they consult with their health care provider before either increasing the dose or abruptly discontinuing the drug.
- Advise patients taking orally disintegrating tablets to peel back the foil on the blister, and, using dry hands, immediately remove the tablet and place in mouth. Advise patients that the tablet disintegrates rapidly in saliva and may be swallowed with or without water.
- Advise patients that if medication needs to be discontinued, it will be slowly withdrawn unless safety concerns (eg, rash) require a more rapid withdrawal.
- Instruct patients to avoid alcoholic beverages and other depressants while taking this medication.
- Counsel patients, families, or caregivers that antiepileptic drugs may increase the risk of suicidal thoughts and behavior and to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm, and to immediately report any of these symptoms to their health care provider.
- Advise patients that drug may cause drowsiness or impair judgment, thinking, or reflexes, and to use caution while driving or performing other tasks requiring mental alertness until tolerance is determined.
- Advise patients that the orally disintegrating tablets contain phenylalanine.
- Advise women to not breast-feed an infant if they are taking clonazepam.
- Advise patients to inform their health care providers if they are taking, or planning to take, any prescription or OTC drug because there is a potential for interactions.
Copyright © 2009 Wolters Kluwer Health.
More Clonazepam resources
- Clonazepam Prescribing Information (FDA)
- Clonazepam Monograph (AHFS DI)
- Klonopin Consumer Overview
- Klonopin Prescribing Information (FDA)
- Klonopin Wafer orally disintegrating tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- clonazepam Advanced Consumer (Micromedex) - Includes Dosage Information
- clonazepam MedFacts Consumer Leaflet (Wolters Kluwer)